Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Cenobamate as an adjunctive therapy for primary generalised tonic-clonic seizures	Cenobamate (YKP3089)	Primary generalised tonic-clonic seizures	Neurology	2022	View \| Download
Cenicriviroc for non-alcoholic steatohepatitis (NASH)	Cenicriviroc (TAK-652; Cenicriviroc Mesylate)	Non-alcoholic steatohepatitis (NASH)	Hepatology	2017	View \| Download
Cemiplimab in combination with chemotherapy for advanced or metastatic non-small cell lung cancer – first-line	Cemiplimab (Libtayo; REGN2810) , Ipilimumab (Yervoy; BMS 734016; MDX 101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Cemiplimab for recurrent, persistent or metastatic cervical cancer – second line	Cemiplimab (Libtayo; REGN2810)	Cervical cancer	Female Reproductive Cancer	2020	View \| Download
Cemiplimab for advanced cutaneous squamous cell	Cemiplimab (Libtayo; REGN2810)	Squamous cell carcinoma (SCC)	Skin Cancer	2017	View \| Download
Cemiplimab as a monotherapy for advanced or metastatic non-small-cell lung cancer whose tumours express PD-L1 – first line	Cemiplimab (Libtayo; REGN2810)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Ceftobiprole medocaril for treating hospital-acquired pneumonia or community-acquired pneumonia requiring hospitalisation in children	Ceftobiprole medocaril	Community-acquired pneumonia , Hospital-acquired pneumonia	Infectious Disease , Respiratory System	2022	View \| Download
Cediranib with olaparib for previously treated platinum resistant recurrent ovarian cancer	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Ovarian cancer	Female Reproductive Cancer	2021	View \| Download
Cediranib in combination with olaparib for recurrent platinum-resistant ovarian cancer – fourth line or greater	Cediranib (Recentin; AZD2171) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
CC-486 for maintenance therapy in acute myeloid leukaemia	Azacitidine (Vidaza; CC-486)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2020	View \| Download